Top Markets
Coin of the day
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc.

AZRX
Pozycja w akcjach #35193
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12... AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
Cena akcji
$3.45
Ostatnia synchronizacja: 2021-09-21
Kapitalizacja rynkowa
$4.29M
Zmiana (1 dzień)
2.07%
Zmiana (1 rok)
0.00%
Kraj
US
Handel AzurRx BioPharma, Inc. (AZRX)

Kategoria

Historia stopy dywidendy dla AzurRx BioPharma, Inc. (AZRX)
Stopa dywidendy (TTM) dla AzurRx BioPharma, Inc. (symbol akcji: AZRX) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla AzurRx BioPharma, Inc. (AZRX) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji